Further strengthening the commitment to quality and regulatory excellence
Mindpeak, a leading developer of AI-powered software for digital pathology, announced it has achieved certification under the EU In Vitro Diagnostic Medical Devices Regulation (IVDR). The certification, issued following rigorous assessment by BSI, a leading EU Notified Body, confirms that Mindpeak's quality management system meets the EU's most demanding regulatory standard for diagnostic software.
Setting a New Standard for AI-Powered Diagnostics
IVDR is widely regarded as one of the most demanding regulatory frameworks in the medical device world, requiring manufacturers to demonstrate robust, auditable quality processes across the full device lifecycle — from design and development through manufacturing, distribution, and post-market surveillance. Achieving this certification places Mindpeak's organizational infrastructure on the same regulatory footing required of every IVD device placed on the EU market.
"Achieving IVDR certification is a defining milestone for Mindpeak - it's proof that our technology doesn't just perform in the lab, it meets the same standard that governs every diagnostic device used in patient care across Europe. This is the foundation we'll build the next phase of our platform on." said Felix Faber, CEO and Founder of Mindpeak.
Built for Scale, Built for Trust
Mindpeak's certified quality management system meets the requirements of ISO 13485 and IVDR Annex IX, as confirmed by BSI Group - a reflection of the standards Mindpeak holds itself to as it builds AI diagnostics for high-stakes clinical use. This milestone reflects the maturity of Mindpeak's regulatory infrastructure as it continues to expand its footprint with laboratories and diagnostic partners across Europe.
By meeting IVDR requirements, Mindpeak reinforces its commitment to delivering AI-powered pathology tools that pathologists and laboratories can trust for high-stakes clinical decision-making - further solidifying the company's position at the forefront of AI-driven precision diagnostics.
More News
#NEWatLSN: Galagos
We are delighted to welcome Galagos as a new member of Life Science Nord e.V.! The founding team answered questions about the company’s initial goals, ...
Read more …
CrystalsFirst Scales Operations...
CrystalsFirst, a leading provider of advanced structural biology solutions and AI-driven drug discovery, is pleased to announce a multi-million-euro expansion of its laboratory infrastructure and ...
Read more …
Indivumed Hosts Onco AI-Med Annual Board Meeting in Hamburg
Indivumed Therapeutics (“Indivumed”) welcomed members of the Oncology Alliance For Individualized Medicine (“Onco AI-Med”) to its global headquarters in Hamburg, ...
Read more …